Development of neuropeptide drugs that cross the blood-brain barrier

被引:96
作者
Egleton R.D. [1 ,2 ]
Davis T.P. [1 ]
机构
[1] Department of Medical Pharmacology, University of Arizona, College of Medicine, Tucson
[2] Department of Medical Pharmacology, University of Arizona, College of Medicine, Tucson, AZ 85724
来源
NeuroRX | 2005年 / 2卷 / 1期
基金
美国国家卫生研究院;
关键词
Antibody based vectors; Blood brain barrier peptide transport; Glycopeptides; Transferrin receptor;
D O I
10.1602/neurorx.2.1.44
中图分类号
学科分类号
摘要
In recent years, there have been several important advancements in the development of neuropeptide therapeutics. Nevertheless, the targeting of peptide drugs to the CNS remains a formidable obstacle. Delivery of peptide drugs is limited by their poor bioavailability to the brain due to low metabolic stability, high clearance by the liver, and the presence of the blood brain barrier (BBB). Multiple strategies have been devised in an attempt to improve peptide drug delivery to the brain, with variable results. In this review, we discuss several of the strategies that have been used to improve both bioavailability and BBB transport, with an emphasis on antibody based vector delivery, useful for large peptides/small proteins, and glycosylation, useful for small peptides. Further development of these delivery methods may finally enable peptide drugs to be useful for the treatment of neurological disease states.
引用
收藏
页码:44 / 53
页数:9
相关论文
共 148 条
[1]  
Ooi G.T., Herington A.C., Recognition of insulin-like-growth-factor-binding proteins in serum and amniotic fluid by an antiserum against a low-molecular-mass insulin-like-growth- factor-inhibitor/binding protein, Biochem J, 267, pp. 615-620, (1990)
[2]  
Zapf J., Schmid C., Guler H.P., Et al., Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia, J Clin Invest, 86, pp. 952-961, (1990)
[3]  
Lalu K., Lampelo S., Nummelin-Kortelainen M., Vanha-Perttula T., Purification and partial characterization of aminopeptidase A from the serum of pregnant and non-pregnant women, Biochim Biophys Acta, 789, pp. 324-333, (1984)
[4]  
Hollenberg N.K., Implications of species difference for clinical investigation: Studies on the renin-angiotensin system, Hypertension, 35, pp. 150-154, (2000)
[5]  
Takenaga N., Ishii M., Nakajima S., Et al., In vivo metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: Pharmacokinetics, isolation, identification, and quantification of metabolites, Drug Metab Dispos, 27, pp. 205-212, (1999)
[6]  
Decarie A., Raymond P., Gervais N., Couture R., Adam A., Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: Influence of enalaprilat, Am J Physiol (Lond), 271, (1996)
[7]  
Reese T.S., Karnovsky M.J., Fine structural localization of a blood-brain barrier to exogenous peroxidase, J Cell Biol, 34, pp. 207-217, (1967)
[8]  
Huber J.D., Egleton R.D., Davis T.P., Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier, Trends Neurosci, 24, pp. 719-725, (2001)
[9]  
Jones H.C., Keep R.F., Butt A.M., The development of ion regulation at the blood-brain barrier, Prog Brain Res, 91, pp. 123-131, (1992)
[10]  
Brightman M.W., Reese T.S., Junctions between intimately apposed cell membranes in the vertebrate brain, J Cell Biol, 40, pp. 648-677, (1969)